@article{uoadl:3482734,
    volume = "8",
    number = "1",
    journal = "Journal of Clinical and Translational Science",
    keywords = "clinical trial; coronavirus disease 2019; drug combination; drug therapy; hospitalization; human; intravenous drug administration; pharmacoeconomics; protocol; public-private partnership; review; therapy",
    BIBTEX_ENTRY = "article",
    year = "2024",
    author = "Keshtkar-Jahromi, Maryam and Adam, Stacey J. and Brar, Indira and Chung, Lucy K. and Currier, Judith S. and Daar, Eric S. and Davey, Victoria J. and Denning, Eileen T. and Gelijns, Annetine C. and Higgs, Elizabeth S. and Jagannathan, Prasanna and Javan, Arzhang Cyrus and Jensen, Tomas O. and Jilg, Nikolaus and Kalomenidis, Ioannis and Kim, Peter and Nayak, Seema U. and Newell, Matthew and Taiwo, Babafemi O. and Yokum, Tammy and Delph, Yvette",
    abstract = "The United States Government (USG) public-private partnership Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was launched to identify safe, effective therapeutics to treat patients with Coronavirus Disease 2019 (COVID-19) and prevent hospitalization, progression of disease, and death. Eleven original master protocols were developed by ACTIV, and thirty-seven therapeutic agents entered evaluation for treatment benefit. Challenges encountered during trial implementation led to innovations enabling initiation and enrollment of over 26,000 participants in the trials. While only two ACTIV trials continue to enroll, the recommendations here reflect information from all the trials as of May 2023. We review clinical trial implementation challenges and corresponding lessons learned to inform future therapeutic clinical trials implemented in response to a public health emergency and the conduct of complex clinical trials during peacetime, as well. © National Institutes of Health, 2024.",
    title = "ACTIV trials: Cross-trial lessons learned for master protocol implementation",
    doi = "10.1017/CTS.2024.507"
}